Investors & Media
News
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
The options have an exercise price of
The equity awards are subject to the terms and conditions of Sage’s 2016 Inducement Equity Plan, and the terms and conditions of equity award agreements covering the grants.
About
Sage Therapeutics is a
clinical-stage biopharmaceutical company committed to developing novel
medicines to transform the lives of patients with life-altering CNS
disorders. ZULRESSO™ (brexanolone) injection is a rapidly acting GABA
modulator now approved by the U.S. Food and Drug Administration as the
first and only treatment specifically indicated for postpartum
depression, pending DEA scheduling. Sage is developing a portfolio of
novel product candidates targeting critical CNS receptor systems,
including SAGE-217, which is in Phase 3 development in major depressive
disorder and postpartum depression. For more information, please visit www.sagerx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190403005281/en/
Source:
Investor Contact:
Maren Killackey, 617-949-4113
maren.killackey@sagerx.com
or
Media
Contact:
Maureen L. Suda, 585-355-1134
maureen.suda@sagerx.com